LucentAD® Complete
Use
LucentAD® Complete is a multi-biomarker blood test designed to assess Alzheimer's disease pathology by measuring Alzheimer's-related biomarkers. The test reduces diagnostic uncertainty by combining four critical biomarkers: p-Tau 217, AB42/40, GFAP, and NfL. This comprehensive panel provides a complete risk assessment for amyloid pathology, enabling earlier and more accurate diagnosis of Alzheimer's disease. The use of these specific biomarkers improves the accuracy of amyloid status classification and reduces the gray diagnostic zone, providing definitive results for more patients.
Special Instructions
The assay is currently not available in New York State. It is a non-invasive, blood-based diagnostic tool that complements other diagnostic modalities. The test is intended for use as part of a clinical evaluation, and results should be interpreted within the context of a comprehensive diagnostic assessment.
Limitations
LucentAD® Complete has not been cleared or approved by the U.S. Food and Drug Administration. Results obtained with the test should be used in conjunction with other diagnostic procedures and clinical assessments. While the test helps assess amyloid pathology likelihood, it is not standalone and should not be solely relied upon for Alzheimer's disease diagnosis.
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
Result Turnaround Time
10 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL
Minimum Volume
0.5 mL
Container
Pearl-top tube, gel barrier tube
Collection Instructions
Draw blood in a pearl-top (K2 EDTA) tube. Invert to mix with preservatives, centrifuge, transfer plasma to a labeled plastic transport tube and refrigerate until time to ship.
Storage Instructions
Refrigerated 7 days, Frozen 7 days, Stable for 3 freeze/thaw cycles
Causes for Rejection
Hemolysis, insufficient volume, improper storage
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 7 days |
| Frozen | 7 days |